Introduction
Bifidobacteria are autochthonous inhabitants of human and animal intestinal tracts, representing 80 and 25% of the infant and adult microbiota, respectively (reviewed in [1] ). This genus comprises widely used probiotics whose benefits are either considered common probiotic core benefits, such as their ability to improve gut microbiota composition [2, 3] and inhibit pathogen adhesion [4] , or are strain specific, particularly, their capability to modulate the host-immune system [5] . This is in line with the ability of bifidobacteria to elicit host responses in a species-and strain-dependent manner [5] [6] [7] . Bifidobacterium bifidum MIMBb75 is a probiotic strain isolated from healthy human feces [8] that resides in cecalcolonic regions and modulates the composition of the gut microbiota in mice [9] ; in a double-blind placebo-controlled study, it was shown to significantly reduce irritable bowel syndrome symptoms and improve general quality of life [10] . Bifidobacterium bifidum MIMBb75 has stronger ability to adhere to intestinal cells in vitro compared to other probiotics such as B. longum NCC2705 and Lactobacillus rhamnosus GG [11] . Bifidobacterium bifidum MIMBb75 possesses several surface proteins that could enable interaction with host cells. These include the bifidobacterial outer protein (BopA), likely involved in the adhesion process [8] , and the murine lytic enzyme TgaA, expressed on the outer surface of B. bifidum MIMBb75 cells and found to activate dendritic cells and trigger IL-2 production in vitro [12, 13] . However, the response of the host to B. bifidum MIMBb75 remains largely uncharacterized, particularly at the molecular level. Gene expression regulation is a main mechanism underpinning the continuous interaction between intestinal tissues and microbiota. The coexistence of prokaryotic and eukaryotic cells in the intestine results in a microbiota-dependent gene expression program in host cells [14, 15] . Not surprisingly, this is affected by probiotic administration, including bifidobacteria [16] . We and others have shown that the intestinal microbiota-dependent gene regulation may occur at the posttranscriptional level, via microRNA, in colon and cecum [17, 18] . MicroRNAs (miRNAs) are 20-22 nucleotides long, noncoding RNAs regulating more than 60% of the human transcriptome [19] . MiRNAs have emerged as fine-tuners of host gene expression contributing to intestinal homeostasis (reviewed in [20] ). Like mRNA, miRNAs are expressed in a time-dependent manner [21, 22] , acting as a response timer to a variety of stimuli. The time-specific response can happen early (within a few hours) such as in gastric epithelial cells exposed to Helicobacter pylori (6 h) [23] or can be delayed (within days), such as in T lymphocytes where miR146-a levels were increased after 8 days to stimulation with phorbol myristate acetate and ionomycin, reaching their highest level of expression after 20 days [24] . miRNA responses to commensal or probiotic bacteria have not been largely investigated. We found that the presence of the microbiota impacts the intestinal miRNA signature including expression of miR-148a [18] . MiR-148a is a member of the miR-148/152 family (reviewed in [25] ) known to play an important role in the regulation of the immune response [26] . Here, we studied the impact of probiotic B. bifidum MIMBb75 on intestinal expression of miR148a and the downstream target gene response in vitro and in vivo.
Materials and methods

Bifidobacteria
Bifidobacterium bifidum MIMBb75, B. bifidum NCC390, and B. longum NCC2705 were grown overnight at 37ЊC in MRS broth (Difco, Detroit, MI, USA) supplemented with 0.05% L-cysteine hydrochloride (cMRS) in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI, USA) containing an atmosphere of 90% N 2 , 5% H 2 , and 5% CO 2 . Prior to use, cells were harvested at 3000 × g for 10 min, washed twice with PBS and quantified microscopically using a Neubauer Bright-Line hemacytometer (Hausser Scientific, Horsham, PA) and by plating on cMRS agar.
Caco-2 cell culture, coincubation, and transfection experiments
Caco-2 cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and were routinely cultured at 37ЊC in DMEM, as previously described [8] . Prior to coincubation with Bifidobacterium strains, the cells were seeded on 6-well culture plates and grown for 2 weeks postconfluency [8] . 
In vivo probiotic studies
Two studies were conducted. The first, which has been partially described in ref. 9 , used 28 5-6 weeks old C57BL/6J male mice purchased from Jackson's Laboratory (Sacramento, CA, USA) and housed at the Division of Comparative Medicine, University of Toronto. After 1 week acclimatization, mice were randomized into two groups (n = 14/group) to receive 0.2 mL of PBS containing 10 8 colony forming unit (CFU) of B. bifidum MIMBb75 cells or PBS only daily for 2 or 14 days via intragastric gavage. The second study used 12 C57BL/6J male mice at the same age and from the same origin as above. Mice received either B. bifidum MIMBb75 or PBS for 2 days (n = 4-8/group). Viability and quantity of B. bifidum MIMBb75 used for gavage were confirmed by plating on cMRS agar. Cecal tissues and contents were collected immediately after dissection on ice and stored at -80ЊC. All animal experiments were approved by the animal ethics committee at the University of Toronto (Protocol number: 20010228). Microbiota composition analysis was by qPCR using TaqMan assays (Supporting Information Table 1 ), as we previously described [9] . 
RNA extraction and real-time quantitative PCR
Total RNA was isolated from Caco-2 cells and mouse cecum tissues using the mirVana TM miRNA isolation kit (Ambion, Life Technologies, Carlsbad, CA, USA) as per the manufacturer's instructions. miRNA and mRNA expression analysis was performed as we described previously [18] (miR-148a, Assay ID: 000470; endothelial PAS domain protein 1 (EPAS1), Assay IDs: Hs01026149_m1 and Mm01236112_m1 for Caco-2 cells and mouse cecum, respectively). MiRNA gene expression data were normalized to the endogenous controls RNU6B (Assay ID: 001093) and sno-135 (Assay ID: 001230) for Caco-2 cells and mouse cecum, respectively. Gene expression was normalized to ACTB (Assay IDs: Hs01060665_g1 and Mm02619580_g1 for Caco-2 cells and mouse cecum, respectively). Fold changes were calculated using the 2 −⌬⌬ Ct method [27] .
Identification of microRNA targets
Putative and experimentally validated targets of miR-148a were identified in silico using the miRWalk database, which integrates seven different algorithms [28] .
Statistical analysis
Statistical significance of miRNA and mRNA expression in Caco-2 cells was determined by one-way analysis of variance followed by Tukey's multiple comparison test. Significance of differential miRNA and gene expression mouse cecum was assessed with the Mann-Whitney test. GraphPad Prism software V5.0 (La Jolla, San Diego, CA, USA) was used for all statistical analyses and values of p < 0.05 were considered significant. Data are presented as mean ± SD.
Results
Bifidobacteria modify miR-148a expression in a strain-and time-dependent manner in vitro
To investigate the miRNA response to bifidobacteria in intestinal cells, Caco-2 cells were incubated for 1, 4 or 24 h with B. bifidum MIMBb75 or B. bifidum NCC390 or B. longum NCC2705. Caco-2 cells viability was ࣙ 93% and viable counts of the three strains were in the range of 2-9 × 10 7 CFU/well at all time points (data not shown). Bifidobacterium bifidum MIMBb75 elicited an increase in miR-148a expression after 1 and 4 h (3.5 ± 1.3 and 2.7 ± 0.7 fold changes, respectively, compared to the control, p < 0.01) but not after 24 h. This increase was more pronounced at the earliest time point. MiR-148a did not change in response to B. bifidum NCC390 and B. longum NCC2705 (Fig. 1). 
Bifidobacterium bifidum MIMBb75 modifies intestinal miR-148a expression in vivo
To determine whether B. bifidum MIMBb75 modulates host intestinal miRNA expression in vivo, we first used tissue samples from a study we had previously conducted, where mice were daily gavaged with 10 8 CFU of B. bifidum MIMBb75 or PBS (as a control) for 2 or 14 days [9] . In the cecum of mice receiving probiotic, B. bifidum counts corresponded to 5.4 ± 0.3 log CFU/g of contents at day 2, while Clostridium coccoides levels were significantly decreased compared to the PBS gavaged mice (8.2 ± 0.1 versus 7.2 ± 0.7 log CFU/g of contents, p = 0.01) (Supporting Information Fig. 1) ; other taxa known to be represented in the gut microbiota, including C. leptum group, were not affected (data not shown). Bacterial counts at day 14 were previously published and showed the same pattern with significantly increased B. bifidum counts and decreased C. coccoides levels in the cecum of mice receiving probiotic [9] . Bifidobacterium bifidum counts increased after 14 days of continuous administration; there was no within group difference between C. coccoides counts at the two time points. The caecal expression of miR-148a increased after 2 days of probiotic treatment (1.4 ± 0.1 fold change, p = 0.002) but not after 14 days (0.9 ± 0.3 fold change) ( Fig. 2A) . Data at day 2 were confirmed in a second independent study showing B. bifidum counts of 6.0 ± 0.4 log CFU/g of cecum content and a significant decrease in C. coccoides counts in mice receiving probiotics compared to the control (6.0 ± 0.4 versus 4.4 ± 0.2 log CFU/g of contents, p = 0.001) (Supporting Information Fig. 1 ). MiR-148a expression was significantly increased (1.7 ± 0.2 fold change, p = 0.005) (Fig. 2B) . These data follow a similar pattern as in Caco-2 cells where the expression of host miR-148a is altered in response to B. bifidum MIMBb75 administration with an early response that differs from that at later time points.
Identification of miR-148a targets
To address the role of miR-148a in host intestinal response to probiotic B. bifidum MIMBb75, its gene targets were identified using seven different algorithms. Over 1760 predicted putative targets for miR-148a were found by at least five of these (Supporting Information Table 2); 78 experimentally validated targets were identified including EPAS1 (Supporting Information Table 3 ). This gene encoding for endothelial PAS domain protein 1 (also known as hypoxia-inducible factor-2 alpha) was identified by five of the seven interrogated algorithms. Previous studies using mesenchymal stem cells had experimentally verified that miR-148a controls the expression of EPAS1 [29] . Thus, this gene was selected for additional investigation in vitro and in vivo.
MiR-148a impacts expression of EPAS1 in intestinal epithelial cells exposed to B. bifidum MIMBb75a
To determine if miR-148a regulates the expression of its target gene EPAS1 in Caco-2 cells in response to B. bifidum MIMBb75, miR-148a was inhibited for 3 days. Then, miR148a-inhibited or mock-transfected Caco-2 cells were incubated with B. bifidum MIMBb75 for 1, 4, and 24 h and miR148a and EPAS1 expression levels were measured by RTqPCR. To ensure that the miRNA inhibition was successful, miR-148a expression levels were also determined in intestinal cells transfected with miR-148a inhibitor and incubated in the presence of vehicle alone (DMEM without antibiotics, supplemented with 100 mM HEPES) for 1, 4, and 24 h. Silencing of miR-148a was efficient since cells transfected with miR-148a inhibitor had a 50 % decrease in miR-148a expression compared to control (miR-148a inhibitor) (Fig. 3) . In cells transfected with miR-148a inhibitor and coincubated with B. bifidum MIMBb75 (miR-148a inh+BB75), silencing was overcome at 4 and 24 h, showing the ability of B. bifidum MIMBb75 to increase the expression of miR-148a. In line with experiments in Fig. 1 , miR-148a increased after 1 and 
h of coincubation of mock-transfected cells with B. bifidum
MIMBb75 (BB75 only). As shown in Fig. 4A , inhibition of miR-148a significantly affected EPAS1 expression compared to the control (miR148a inhibitor) with more than 200% increase in gene expression in the miR-148a silenced group in response to the probiotic strain at 4 h (miR-148a inh+BB75) (p < 0.001). This gene was also found to be significantly downregulated in the cecum of mice gavaged with B. bifidum MIMBb75 for 2 days (0.8 ± 0.1 fold change, p = 0.004) (Fig. 4B) . This indicates that downregulation of EPAS1 gene expression by B. bifidum MIMBb75 is mediated by miR-148a.
Discussion
In this study, we showed that the expression of miR-148a is altered in intestinal cells in response to bifidobacteria in a strain and time-dependent manner. In particular, exposure to B. bifidum MIMBb75 induces an early upregulation of miR148a both in vitro and in vivo, which disappears at later time points. Very few studies have investigated the effect of selected probiotic on miRNA expression. Lactobacillus rhamnosus GG was found to increase the expression of miR-155 and decrease miR-146a in human dendritic cells [30] . Escherichia coli Nissle 1907 increased tight junction protein expression in T84 cells via miR-595, miR-483, and miR-203 downregulation [31] . Heat-treated L. paracasei NCC 2461 downregulated miR27a in peripheral blood mononuclear cells [32] . Enterococcus faecium NCIMB 10415 upregulated miR-423-5p and downregulated its target gene IGLC (immunoglobulin lambda light C region) in the intestine of piglets [33] . These studies show that different probiotics elicit different miRNA responses. Though, none of them examined the effects of different probiotics on the same miRNA species. We found that, opposite to B. bifidum MIMBb75, B. longum NCC2705 and B. bifidum NCC390 did not affect miR-148a expression. The molecular mechanisms behind this strain-specific response are not clear. Recently, B. bifidum MIMBb75 whole genome sequencing revealed the presence of a gene named tgaA coding for a murein lytic enzyme TgaA [12] . This peptidoglycan-degrading enzyme was shown to exert an immunomodulatory effect by inducing Dendritic cells (DCs) activation and IL-2 production through its C-terminal cysteine histidine-dependent amidohydrolase/peptidase domain in a strain-dependent manner, with B. bifidum MIMBb75 showing the strongest effect [13] . Therefore, it is tempting to speculate that miRNA-mediated B. bifidum MIMBb75-host interaction depends on the cysteine histidine-dependent amidohydrolase/peptidase domain of TgaA. Two extracellular proteins encoded by B. bifidum, the sortase-dependent pili and the type IV tight adherence locus, have been shown to mediate its interaction with the host [34] [35] [36] . However, opposite to TgaA, these proteins are encoded by genes identified in B. bifidum core genome [37] , and are thus unlikely to explain strain-specific responses. Microbial metabolites such as short chain fatty acids may regulate host gene expression epigenetically [38] offering a possible alternate mechanism for host miRNA modulation. The microbiota is a modifier of the intestinal miRNA response to pathogen exposure, in that the expression of miR-148a was reduced in the intestine of conventional, but not germfree mice, infected with Listeria monocytogenes [39] . Bifidobacterium bifidum MIMBb75 modifies the microbiota, resulting in increased bifidobacteria and decreased C. coccoides counts (this study and [9] ), although, this is already evident at day 2, with no differences between day 2 and 14. Thus, there could be a "direct" effect of B. bifidum MIMBb75, which is not mediated by the microbiota, although, given its complexity and because the effect of B. bifidum MIMBb75 administration on its composition and activity have not been completely elucidated yet, future studies including microbiota profiling are necessary. miRNAs respond to bacterial stimuli in a time-dependent manner. For example, pri-miR-147 increased in murine peritoneal macrophages after 2, but not 6 h of exposure to lipopolysaccharide [40] and the expression of miR-146a in gastric epithelial cells increased between 6 and 9 h after H. pylori infection, but decreased after 24 h [23] . However, the deferred response to bacterial exposure has not been investigated in the literature. Early responses have been deemed essential in innate immune responses where a short reaction time is critical for resistance, for example, to a pathogenic microorganism. On the other hand, delayed responses may play a role in adaptive immunity [24] . Thus, our data suggest that the intestine may adapt to B. bifidum MIMBb75 following continued exposure. The time of exposure to a probiotic is a critical factor in clinical practice because it dictates the administration protocol. A time-dependent response following probiotic exposure was found in vitro and in vivo (mouse cecum) for B. bifidum PRL2010 impacting the immune response via alteration of the gene expression signature of HT-29 cells with more consistent changes after 4 h, rather than 1 or 2 h, of coincubation [41] , and in vivo for Lactobacillus reuteri 100-23 impacting inflammatory pathways after 6 but not 21 days of colonization [42] . Taken together with our findings, these data suggest that there may be an immediate intestinal response to probiotic exposure that may vary from that resulting from repetitive reinoculation. This concept aligns with a study showing that, opposite to continuous supplementation, pulse administration of probiotics maintains high expression levels of mucin 3 in the jejunum and ileum of rats [43] .
Based on in silico analysis, several genes were identified as potential targets of miR-148a, including experimentally validated EPAS1. This is a hypoxia-inducible transcription factor of the basic helix-loop-helix/PAS domain family, also known as hypoxia inducible factor-2␣ [44] . High levels of EPAS1 have been associated with digestive system cancers (reviewed in [45] ), IBD [46] , and colitis [47] . In a mouse model, EPAS1 was found to activate mediators of inflammation such as TNF-␣ and to promote colonic inflammation and spontaneous colitis after Citrobacter rodentium infection or dextran sulfate sodium administration [47] . Moreover, it has a role in activating iron transporters [48] and intestinal knockout of EPAS1 significantly decreased tissue iron accumulation, due to a decrease in iron absorptive genes, in a mouse model of sickle cell disease [49] . Therefore, intestinal EPAS1 has been suggested as a therapeutic target for IBD [47] , sickle cell disease [49] , and different types of cancers [50] . Here, we found that B. bifidum MIMBb75 increased miR-148a resulting in downregulation of EPAS1 in colonic cells. This suggests that B. bifidum MIMBb75 could be considered for maintenance of, or to restore, intestinal homeostasis.
In conclusion, our study brings a new concept of strainspecific bifidobacteria-host crosstalk mediated by microRNA. Our findings show that B. bifidum MIMBb75 stimulates gene expression changes in the host at both the transcriptional and miRNA levels in a time-dependent manner. Although speculative at this stage, the use of B. bifidum MIMBb75 may be considered to inhibit EPAS1 function in intestinal cells and as a consequence help in preventing or mitigating colitis and other diseases. Molecular antagonists of EPAS1 have been identified [51] , providing therapeutic opportunities to its inactivation in disease. Our study is the first to show an alternative way to achieve EPAS1 inhibition in intestinal cells that is mediated by miRNA in response to a probiotic. This warrants further research to better elucidate the mechanisms involved. In addition, timing of probiotic administration may play an important role in clinical practice. 
